Click cover above to view the Conference Guide

113 Pages·2012·8.89 MB·English

W
E
L
M C
O
M
E
U
R
O
P
H
A
F R
M
A
L
IC
E
N
R S
IN
G
O G
R
O
U
T P
S
12th Annual
S
E BIOTECH IN EUROPE
V S
P
E
A
N INVESTOR FORUM K
E
R
S
I

E
1st-2nd October 2012
P
P R
Hilton Zurich Airport Hotel, Switzerland E
S
E
N
O T
IN
G
R C
O
M
P
A
U Conference Guide N
IE
S
E

N
S
U
P
P
I O
R
T
IN
G
H O
R
G
A
N
C IS
A
T
E ION
S
T
O
I OR
www.sachsforum.com G
A
B N
IS
E
R
S
W
E
L
n C
e O
xtu ME
Welcome
P
Sachs Associates are delighted to welcome you to the: H
A
R
M
A
12th Annual LIC
E
N
S
Biotech in Europe IN
G
G
R
Investor Forum O
U
P
S
1st-2nd October 2012
Hilton Zurich Airport Hotel, Switzerland
Sachs Associates are delighted to welcome you to the 12th Annual Biotech in Europe Investor
S
Forum. Following the success of previous years, the forum once again provides access to an P
E
A
exciting cross-section of venture-funded and small-cap companies with leading investors and K
E
pharmas. R
S
This Forum is highly transactional and is comprised of a series of panels and presentations
from leading investment, pharmaceutical and biotech companies, each one providing an expert
outlook on growth and investment activity in Europe’s Biotech industry.
The programme highlights the current issues surrounding the evolving M&A market, the Private
P
Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, R
E
this year’s programme features more than 70 company presentations from a range of publicly S
E
N
listed and private life science companies looking to raise finance and/or find partners. T
IN
G
C
O
M
P
General Information A
N
IE
The registration desk will be open from 8am on October 1st and from 8.15am on October 2nd S
although you are welcome to join the event at any time. Please collect a copy of the agenda for
information on timing and room allocation for each session.
Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to
all participants. S
U
P
A Networking Lunch will be set up in the Zurich A & B rooms. P
O
R
Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the T
IN
event. G
O
R
G
A
Request for Presentations NIS
A
Please use the agenda to mark off presentations that you are interested in and email your request T
IO
to [email protected] after the conference. We will endeavour to send you the requested N
S
presentations as soon as we have been granted permission to do so by that specific presenter.
Please note that we DO NOT have copies of the slides that are shown during the conference.
O
R
G
A
N
IS
E
R
S
t W
b E
a L
c C
k O
M
E
Events Diary
P
For regular updates, sponsorship, presenting and attending opportunities H
A
and further information regarding any of our future events please contact R
M
A
Zoe Harris on [email protected] L
IC
E
N
S
IN
6th Annual G
G
R
European Life Science CEO Forum O
U
P
For Partnering & Investing S
5th – 6th March 2013 • Zurich • Switzerland
Back for its sixth year, this exclusive and highly transactional partnering event is a must for
companies wishing to meet with their peers, engage with leading investors and forge new
S
partnerships. P
E
A
Building on the success of this year’s event, the forum will provide an excellent platform to gain KE
R
insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the S
Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants.
The conference will feature up to 8 presentations by large to mid size pharmaceutical companies
looking for strategic alliances/partners.
P
Do not miss out on this great opportunity to meet emerging companies, leading global investors and R
E
Big Pharma representatives! S
E
N
T
IN
G
C
Annual O
M
P
Cancer Bio Partnering Forum A
N
IE
Promoting Public & Private Sector, Collaboration S
& Investment in Drug Development
21st – 22nd May 2013 • Boston • USA
S
U
P
P
13th Annual O
R
T
Biotech in Europe Investor Forum IN
G
O
30th September – 1st October 2013 • Zurich • Switzerland R
G
A
N
IS
A
T
IO
N
S
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Pharma Licensing Groups
Pharma P
www.amgen.co.uk H
A
Licensing R
M
A
Groups L
www.astellas.eu IC
E
represented N
S
IN
at the G
G
www.biogenidec.co.uk R
Forum O
U
P
S
www.helsinn.com
www.ipsen.com
S
P
E
A
K
E
www.jnj.com R
S
www.menarini-biotech.com
P
R
www.merck.com E
S
E
N
T
IN
G
www.merckserono.co.uk/en/index.html C
O
M
P
A
N
www.norgine.com IE
S
www.novartisoncology.com
S
U
P
P
www.novartisvaccines.com OR
T
IN
G
O
R
www.pierre-fabre.com G
A
N
IS
A
T
IO
www.roche.com N
S
www.sanofi.com
O
R
www.nycomed.com GA
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
P
H
A
Alexey Eliseev, Managing Director, Maxwell Biotech R
M
Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the A
L
Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry IC
and venture capital. EN
S
Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in IN
Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, G
G
University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later R
O
Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The U
company used a novel drug discovery technology developed in several academic labs, including Eliseev’s group in Buffalo. P
S
He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos
was acquired by Amgen in 2007 for $300 million.
Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC
Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture
Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous t
deals with portfolio companies in the US and Europe. b S
ack PE
Allan Marchington, Partner, Apposite Capital :: n AKE
ex R
Allan is a founder and Partner at Apposite Capital a London based healthcare investor. Allan was formerly at Abingworth tu S
management and prior to this was a member of Millennium Pharmaceuticals management team as an Senior Vice President
with responsibility for technology Investments. He also served as Chairman of Millennium Pharmaceuticals in Europe. Allan
joined Millennium following their acquisition in July 2000 of Cambridge Discovery Chemistry, where he was CEO and founder.
Allan began his career as a medicinal chemist at Pfizer Central Research.
Allan is a Board member of the BioIndustry Association, Ambit Biosciences Inc., Ambrx Inc., Anaphore Inc., and Convergence P
R
Pharmaceuticals Ltd. E
S
E
N
T
IN
Dr Andreas Caduff, CEO, BioVoition AG G
C
Andreas was born in 1971 and is a Swiss citizen. He held various positions in the pharmaceutical and medical device O
M
industry. In his previous position he was serving as CTO of Solianis Monitoring AG, a company focusing on noninvasive P
A
glucose monitoring. At Solianis, he orchestrated the overall technology and product development, experimental/clinical N
study strategies, regulatory considerations, external technical communication and interaction with the industrial/scientific IE
S
community, regulatory bodies as well as the investor’s community. He is an expert in physiological monitoring techniques
and involved physiological/metabolic processes, combining the expertise in various fields relevant to the development,
industrialisation and commercialisation of such technologies. Dr. Caduff is a frequent invited speaker at industrial and
scientific conferences and meetings on physiological monitoring, mobile Health and related subjects. He has innovated
numerous patents and co-authored several dozen scientific publications in peer reviewed journals. He holds a BSc degree
S
in Chemistry from the University of Applied Science, Winterthur, Switzerland, an MSc degree in Biotechnology and a Ph.D. in U
P
Biophysics from the University of Teesside, UK and the Hebrew University of Jerusalem, Israel. P
O
R
T
IN
G
Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Oncology O
R
G
Anne is a Vice President in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her A
N
responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. In IS
this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing A
T
alliances. IO
N
Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in S
Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of
Novartis in 2004 as a Project Leader. There she led numerous multidisciplinary Project Teams through the generation and
implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked
as a Project Manager at Merck & Co. for close to 4 years and as a Visiting Research Scientist for 2 years.
Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral O
R
fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell G
A
University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business N
Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA. IS
E
R
S
W
E
L
C
O
M
E
Speakers
P
H
A
Arthur Franken, Partner, Gilde Healthcare Partners R
M
Arthur joined Gilde in 2001. He led the investments in Conatus Pharmaceuticals, FlowCardia (acquired by C. R. Bard), A
L
Moximed and MTM Laboratories (acquired by Roche). He has been involved in numerous investments and divestments IC
including Ablynx (IPO on Euronext), Agendia, uniQure, BG Medicine (IPO on NASDAQ) and Pieris. EN
S
He represents Gilde on the board of Moximed and Symphogen. He served as a board member for FlowCardia (until its trade IN
sale to C. R. Bard), MTM Laboratories (until its trade sale to Roche) and observed on the boards of Agendia and AMT (until G
G
its IPO on Euronext). R
O
Prior to joining Gilde he gained experience in cardiovascular research at the Leiden/Amsterdam Center for Drug Research U
P
and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch S
national.
Bassam Damaj, CEO & President, Apricus Biosciences
t
Bassam has been the President, Chief Executive Officer and a director since December 2009. Dr. Damaj served as Chairman
osfoifn utcnhede e 2Br0 oo1af 0rRd.& HoDfe HDiseir aetlhcthetoc rcasor e-frf. ooHumen idOse cart ocobof e-Cfro e2ull0nted1ke0 r B tooiof tABepicorh-ilnQ 2ou0lao1ng2ty,. IanHnced. ahsnaedsr vsseeedrrv vaeesdd aaas sd tiahre emc Cteohmri efbfr eoErmx eo cf1 uo9tu9ivr7e a Oudn ffihticol ec2r 0Fai0nn0da. n CHcheei e Cifs oS maclismeoni ttttihefieec back :: n SPEAKE
Ooff fiNceewr aTnadrg ae td Iinretecltloigre onfc Be ioa-nQdu aa nGt rsoiunpc eL eitasd ienrc efoprt ioimn minu Jnuonloeg i2c0a0l 0an. dH ein hflaasm amlsaot osreyr vdeisde aasse t hper oGgrroaumps L aeta Tdaenr afboer tRhees Oeaffircche extu RS
Laboratories, U.S.A., Inc., as a senior scientist and member of the senior staff board of the drug discovery department at
Pharmacopeia Inc., and as a visiting scientist at Genentech Inc., Pfizer Inc. and the National Institutes of Health (NIH). He also
served as an independent director for CreAgri, Inc. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval
University and completed a postdoctoral fellowship in molecular oncology from McGill University.
P
R
E
S
Dr Benedkt Timmerman, CEO, Genticel E
N
T
Benedikt founded Genticel (initially called BT Pharma) in 2001 and is currently CEO of the company. Prior to Genticel, IN
G
Benedikt had a successful career at NOVARTIS (1996 – 2000) and its predecessor company SANDOZ (1991 - 1996). C
In these companies, he held various management positions, including Head of Biotechnology, Sandoz Seeds Eu, Senior O
M
Director Research & Development of Novartis Seeds – Eu, member of the European Executive Committee and member of the P
A
corporate Novartis Technology Licensing and Acquisition team. Dr Timmerman is also board member of several organisations, N
including BioMedicalAlliance, a French Biotech Association and Biotech Representative of the Industrials Club of the ‘Cancer IES
Pole GSO’ in France. Benedikt is of Belgian nationality, holds a PhD in Molecular Genetics from the University of Ghent,
Belgium (1986) and an MBA from INSEAD, Fontainebleau, France (1990-1991).
Bill Blair, BioQuarter
S
U
Bill joined BioQuarter as the Head of Business Creation in April 2011. He is responsible for managing the launch of new P
P
companies from the BioQuarter portfolio, as well as leading a team of professionals in the development of further new O
R
businesses based on world-leading medical research from the University of Edinburgh’s College of Medicine and Veterinary T
IN
Medicine and NHS Lothian. G
O
Prior to joining Edinburgh BioQuarter, Mr Blair was Investment Director at Scottish Widows Investment Partnership (SWIP) R
G
for eight years where he established and led its venture capital investment programme before setting up his own venture A
N
capital strategic consultancy business, HVS Advisers. Mr Blair also previously headed up pharmaceutical company research IS
for stockbrokers Nomura International, Fleming Securities and Greig Middleton. Before moving into investment, he worked in A
T
various commercial functions in the pharmaceutical industry for seven years. IO
N
He holds a BSc (Hons) in Biological Sciences and an MSc in Business Administration from Edinburgh University. S
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
P
H
A
Blake M. Paterson, Co-Founder & CEO, Cerecor, Inc. R
M
Physician-Executive / Entrepreneur with ability to lead drug hunting, translational medicine, product development, registration, A
L
finance & commercialization operations. Successful company builder with experience in licensing, marketing, strategic IC
planning / portfolio management, global clinical research and affiliate operations within small and large organizations. Device EN
and therapeutics tech transfer. Proven fundraiser, able to develop and communicate vision throughout the organization and SIN
in the marketplace. Successful in exploiting biomedical business opportunities in EU, North And South America; trilingual. G
Specialties: Clinical medicine, drug hunting, translational medicine, product development, registration, finance & G
R
commercialization operations in therapeutics and medical devices. Product licensing, marketing, strategic planning / O
U
portfolio management, global clinical research and affiliate operations within small and large organizations. Board Certified P
S
in Anesthesiology (ABA).
Carina Schmidt, CEO, Athera Biotechnologies AB
Carina is Chief Executive Officer, Athera Biotechnologies AB (publ), a Karolinska Development portfolio company. t
Mprso dSucchtm midatn haagse mexepnet rwieinthcien ftrhoem Lnifeea rSlyc ie3n0c yee aarresa i.n Fionrdmusetrr ym, manaaingleym ine nbtu csoinnessusl tadnetv,e ilnotpemrimen tC, EinOte arnnadt ibounsailn mesasr kaedtivnisgo ar ntdo back SPE
several biotech start-ups. During years 1985 to 2000 she has worked with Pharmacia Biotech/Amersham Biosciences (now :: n AKE
GE HealthCare), founded Grasp Bioscience AB in year 2000 and co-founded BioBusiness Partners Scandinavia in year 2006. ex R
Board Director in Genovis AB (publ) and Member of the Investment Committe in Innovationsbron AB Region Mitt. Lecturer in tu S
“Entrepreneurship in Biotechnology” at Umeå University and Umeå Biotech Incubator.
Carlos Buesa, CEO, Oryzon
P
R
Carlos earned his PhD in Biochemistry from the University of Barcelona in Spain. E
S
He has produced more than thirty papers and patents internationally, was a member of the cellular signaling research team E
N
in the Pharmacy Faculty at the University of Barcelona, held an EU post-doctoral fellowship in the Faculty of Medicine at the TIN
University of Ghent in Belgium, and later became Senior Investigator with the Flemish Institute of Biotechnology (VIB), also G
in Belgium. C
O
M
In 2000, he founded Oryzon, one of the strongest-growing biotech companies in Spain, and since 2001 he has served as P
A
Chief Executive Officer and Chairman of the Board of Directors. N
In addition, he sits on the board of other biotech companies like Neurotech Pharma and Oncnosis Pharma. He has taken the IES
executive education programme (PADE) at the IESE Business School.
Currently he is President of the Association of Catalan Biotechnology Companies CataloniaBio, and he is a member of the
governing body of ASEBIO and of the Executive Committee of BioRegió de Catalunya, a new regional development model that
has been set up with the aim of improving people’s quality of life through better coordination of the biotechnology activity
being carried out in Catalonia. S
U
P
P
O
R
T
Carlos de Sousa, VP Corporate Licensing, Takeda Pharmaceuticals International GmbH IN
G
O
Carlos is Vice President, Head of Commercial Licensing at Takeda. He was previously Vice President of Corporate Licensing R
G
at Nycomed, which was acquired by Takeda in 2011. A
N
Prior to joining Takeda-Nycomed, Dr. de Sousa was Chief Business Officer at Newron Pharmaceuticals SpA in Italy, where he IS
A
was responsible for the company’s growth strategy, including its in- and out-licensing, and mergers & acquisitions activities. T
IO
Before Newron, Dr. de Sousa was Global Head of Business Development and Licensing at Schwarz Pharma AG in Germany N
S
and prior to that served as Head of Global Negotiations at Novartis Pharma AG, based in Switzerland. At the latter he was also
European Business Head for the Respiratory and Dermatology Franchise.
Dr. de Sousa started his career in the pharmaceutical industry with Pfizer in 1989, as Medical Director in Portugal. He then
joined the Pfizer Corporation in New York, USA, where he was initially appointed International Medical Director and, subsequently,
Director of Corporate Licensing and Development and Director of Medical and Regulatory Affairs for Latin America.
O
Dr. de Sousa earned his M.D. degree from Lisbon University, Portugal in 1983 and his Executive M.B.A. from New York R
G
University, USA in 2000. A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
P
H
A
Carlos Paya, CEO, Immune Design Corp. R
M
Carlos joined Immune Design Corp. in May 2011 as President and Chief Executive Officer. He previously served as President A
L
of Elan Corporation and led the biotechnology company’s commercial, marketing, clinical, research, and development teams IC
from 2008 to 2011. Before joining Elan, Dr. Paya was at Eli Lilly & Company as Vice President, Lilly Research Laboratories EN
where he led various therapeutic areas encompassing discovery, clinical development, and the Diabetes and Endocrine SIN
franchise. Prior to this, Dr. Paya was Professor of Medicine, Immunology, and Pathology, and Vice Dean of the Clinical G
Investigation Program at the Mayo Clinic in Rochester, Minnesota. He received his MD and PhD degrees from the University G
R
of Madrid and underwent postdoctoral training at the Institute Pasteur, Paris, France. O
U
P
S
Carole Nuechterlein, VP Corporate Licensing, Takeda Pharmaceuticals International GmbH
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the
pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where
she was General Counsel. t
CSMya&nroAtel,e xC /bRaeorogclahene l eihnde Ptrh aceloa n rAeelegtoro ,t wiCaoatirlokifnion rtgne iaaam tf o Sfcokuars dtihndege nRo noA crMhpe&s AaS,cl arqetuesi seMiatireocanhgs c hooeflr laG &bly ocFrAalortmito an nisnd a tTnhhdee lriMcaep&neAsu itngicgro Hdueupam. lsFa.rn oD mPuoe lt yhtocel orhene,ar slbsha.ec kwgororkuendd aint back :: n SPEAKE
She currently serves as a board observer at Aileron, Alios, Ambit, Ambrx, Conatus, Envoy, Idaho Technology and Nereus. extu RS
She has a BA from Valparaiso University and a JD from University of Michigan. More information on the Roche Venture Fund
can be found at www.venturefund.roche.com.
Catherine Pickering, Head of Oncology, Merck Serono P
R
E
Specialties: Leading a team of BD professionals focussed in the oncology licensing field. Licesning of preclinical and clinical S
E
stage products within biotechnology and pharmaceutical companies. N
T
Technology Transfer within UK Oncology Research Institution for four years. Responsible for protecting and exploition the IN
Institution’s IP. G
C
More recently business development role within Oncology company. O
M
P
A
N
IE
S
Chirs Britten, Independent Consultant
Chris has a scientific background, a PhD in biochemistry and an MBA. Chris has gained huge experience and contacts
in the Life Sciences market having negotiated a variety of acquisitions, licences, divestments and strategic alliances with
partners around the world. S
U
Current activities include advising clients across the spectrum of the Life Science sector, from molecular diagnostics to P
P
biotechnology, generics to specialty pharmaceuticals and OTC products. O
R
T
IN
G
O
R
G
Christof Boehler, CEO, Pantec Biosolutions A
N
After finishing his PhD in chemistry at ETH Zurich dealing with bio-polymeric drug release systems, Dr. Christof Böhler moved IS
A
to the United States for a Postdoc at the Salk and Scripps Research Institutes in La Jolla (CA, USA) carrying out bio-medical T
IO
basic research. N
S
From there he started to work as the head of development for a start up biotech company in Zurich, whose process has
now been commercialized. Realizing the need to develop his commercial know-how, he moved into product management of
research chemicals and biologicals at Fluka Chemie AG (a Sigma Aldrich company, Buchs, CH).
During his Fluka time he completed a postgraduate executive degree in “International Management” at the FH Liechtenstein
and UBC Vancouver (Canada). His further career involved Business Development Manager Europe and Business Manager
O
for Maybridge, a Drug Discovery service company, and finally Marketing Director “Drug Discovery Chemicals” for Acros/ R
G
Maybridge (Fisher Scientific). A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
P
H
A
David Slack, Head of Corporate and Business Development, NovImmune SA R
M
David brings nearly 20 years of senior management and business development experience, and joined NovImmune in 2012. A
L
David has a track record of innovation in business development, fundraising and in senior management positions at public IC
and private biotech as well as large pharmaceutical companies. His deal-making experience encompasses nearly $1 billion EN
in corporate partnerships, spin-outs and financings. SIN
Prior to joining NovImmune, David co-founded and served as Chairman, President and CEO of Kinagen, an innovative next G
G
generation kinase drug discovery and development company. Under David’s leadership, Kinagen advanced programs and R
O
established collaborations targeting cancer, inflammatory, fibrotic and ocular diseases, and was sold in 2011. Prior to Kinagen, U
David served as Vice President of Business Development at Isis Pharmaceuticals, where he was responsible for several major P
S
partnerships and for the GeneTrove functional genomics division. From the “buy side” corporate partnering perspective,
David served in senior business development positions as Rhône-Poulenc Rorer and Aventis Pharmaceuticals, where he was
responsible for multiple major strategic partnerships, and served as the business representative to the Genomics Task Force.
David has played key roles in securing financing for emerging companies and has provided consulting services to a range of
pharma, biotech and medical device companies as well as investor groups.
t
b S
ack PE
Deborah Harland, General Partner, SR One :: n AKE
ex R
Deborah joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, tu S
drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and
business development during her more than 20 year tenure in the pharmaceutical industry. Deborah is currently a member
of the Board of Directors of Mission Therapeutics Limited, Protaffin AG, Bicycle Therapeutics Limited, Syntaxin Limited, and
f-star GmbH. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange,
2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and
P
7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from R
E
the University of London, and her MBA from Henley Management College. S
E
N
T
IN
G
Eduardo Bravo, Managing Director & CEO, TiGenix C
O
Eduardo has more than 20 years experience in the bio-pharmaceutical industry. His professional career includes several senior M
P
management positions at Sanofi-Aventis, including Vice President for Latin America, where he was in charge of more than 2000 A
N
employees and oversaw sales of more than €1 billion. At Sanofi-Aventis he also held positions such as Marketing and Sales IE
Manager for Europe and General Manager for Belgium. He also worked for 7 years in SmithKline Beecham in sales positions S
both nationally and internationally. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). Mr. Bravo is co-
chair of the Alliance for Advanced Therapies (AAT) and member of YPO. He is an executive Board member of TiGenix.
S
U
Edwin Moses, CEO, Ablynx P
P
O
After completing his post-doctoral research in Germany, Edwin Moses began a commercial career with successful periods R
T
spent at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001, first as CEO and later as Chairman, he IN
G
was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a flotation (LSE) in O
1998 at a value of £120 million. This was followed by a sale of the company to Evotec Biosystems in 2000 for £316 million. R
G
During this period, OAI grew from four people to over 250. Over the past eight years, Edwin has played an important role at A
N
Board level (primarily as Chairman) in over 15 European life science companies. During this time he has been involved in a IS
number of financing rounds, a series of M&A transactions and four IPOs. He has been Chairman of Ablynx since 2004, and AT
in 2006 he extended his role as Chairman to include that of Chief Executive Officer. IO
N
S
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
P
H
A
Eric de La Fortelle, CEO, Delenex Therapeutics R
M
Eric is CEO of Delenex Therapeutics AG, a Zurich-based biotechnology company focused on biologic medicines delivered A
L
locally for chronic diseases, and administered systemically for acute diseases. The company is currently focused on IC
generating clinical efficacy data in patient studies in three areas: psoriasis, inflammatory bowel disease and acute systemic EN
inflammation. It also uses its proprietary PENTRA® platform to generate a full pipeline of highly stable small antibodies that SIN
have comparable affinity and other drug-like properties to existing antibodies, but superior tissue penetration properties and G
rapid clearance, thus enhancing safety for patients. G
R
O
Formerly, Eric was Global Head, External Research and Technologies, for Roche. During six years there, he headed a worldwide U
group with a global mandate to find partners, establish contracts and manage alliances with companies offering innovative P
S
technologies for every stage of product discovery, development and life cycle.
Eric is a scientist by training, with contributions in the field of structure-based drug design (determination of 3D structures of
protein targets by X-ray crystallography).
He has extensive experience of negotiating Pharma/Biotech alliances (both from the Biotech and the Pharma side). He was
trained as an engineer and Physicist at Ecole Centrale de Paris, holds a Ph.D. in Biophysics from Paris XI University, and an t
MBA from INSEAD. b S
ack PE
Erik van den Berg, CEO, AM-Pharma B.V. :: nex AKER
AM-Pharma is a biopharmaceutical company, engaged in the development of novel human alkaline phosphatase therapeutics tu S
for unmet needs in severe inflammatory diseases. The Company’s lead programs for this therapeutic enzyme are in Acute
Kidney Injury and Inflammatory Bowel Disease.
Strong, positive results from Phase II clinical studies using native bovine alkaline phosphatase demonstrated the efficacy of
this treatment in patients with Acute Kidney Injury and Moderate-to-Severe Ulcerative Colitis (a type of Inflammatory Bowel
Disease), thereby providing proof-of-concept for the development of recombinant human alkaline phosphatase. P
R
E
AM-Pharma’s proprietary human form of this enzyme has been optimized for treating inflammatory conditions and is being S
E
produced by cGMP manufacture for preclinical and clinical trial supply and commercialization. N
T
AM-Pharma discovered that a key function of alkaline phosphatase is to protect organs against inflammation and tissue IN
G
damage. While alkaline phosphatase is found in many cells of the human body, it is present at reduced levels in certain C
O
diseases including Acute Kidney Injury and Ulcerative Colitis. The Company’s proprietary therapeutics are disease modifying M
therapies and have the potential to be “first-in-class” medicines. P
A
N
The Company’s business strategy is to advance its human alkaline phosphatase therapeutics through to Phase II development IE
in Acute Kidney Injury, before seeking partners for further clinical development and commercialization. AM-Pharma is currently S
seeking strategic partners for the further development of its therapeutic in Ulcerative Colitis. Founded in 2001, AM-Pharma
is a private company that is based in Bunnik, the Netherlands. The Company is backed by a strong syndicate of international
investors and has raised over €55 million equity to date.
S
U
P
Esteban Pombo Villar, Chief Operating Officer, Oxford BioTherapeutics AG P
O
R
Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 T
years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of IN
G
Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept O
R
in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz G
A
Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative N
projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry. IS
A
T
IO
N
S
Francis Marsland, Head of EU Corporate Development, Biogen Idec
Francis is the Site Leader of Biogen Idec’s International HQ in Zug, Switzerland. As VP, European Corporate Development,
Francis is responsible for sourcing and transacting European business development and M&A opportunities. Francis advises
on Biogen Idec’s European Corporate Strategy, Corporate Communications, Investor Relations, and Government Affairs.
Francis was previously Biogen Idec’s Chief International Counsel. O
R
G
A
N
IS
E
R
S